Research programme: eye disorder therapies - Calmune Corporation/ribOvax BiotechAlternative Names: AC-8
Latest Information Update: 16 Jul 2016
$50 / €47 *
At a glance
- Originator Calmune Corporation
- Developer Calmune Corporation; ribOvax Biotechnologies
- Class Monoclonal antibodies
- Mechanism of Action Virus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpesvirus infections; Ophthalmic infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpesvirus-infections in Switzerland (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ophthalmic-infections in Switzerland (Topical)
- 06 Nov 2009 New profile.